These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 19477958

  • 1. Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice.
    Sumner CJ, Wee CD, Warsing LC, Choe DW, Ng AS, Lutz C, Wagner KR.
    Hum Mol Genet; 2009 Sep 01; 18(17):3145-52. PubMed ID: 19477958
    [Abstract] [Full Text] [Related]

  • 2. Transgenic inactivation of murine myostatin does not decrease the severity of disease in a model of Spinal Muscular Atrophy.
    Rindt H, Buckley DM, Vale SM, Krogman M, Rose FF, Garcia ML, Lorson CL.
    Neuromuscul Disord; 2012 Mar 01; 22(3):277-85. PubMed ID: 22079083
    [Abstract] [Full Text] [Related]

  • 3. Activin Receptor Type IIB Inhibition Improves Muscle Phenotype and Function in a Mouse Model of Spinal Muscular Atrophy.
    Liu M, Hammers DW, Barton ER, Sweeney HL.
    PLoS One; 2016 Mar 01; 11(11):e0166803. PubMed ID: 27870893
    [Abstract] [Full Text] [Related]

  • 4. Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy.
    Rose FF, Mattis VB, Rindt H, Lorson CL.
    Hum Mol Genet; 2009 Mar 15; 18(6):997-1005. PubMed ID: 19074460
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of myostatin and related signaling pathways for the treatment of muscle atrophy in motor neuron diseases.
    Abati E, Manini A, Comi GP, Corti S.
    Cell Mol Life Sci; 2022 Jun 21; 79(7):374. PubMed ID: 35727341
    [Abstract] [Full Text] [Related]

  • 6. Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset.
    Feng Z, Ling KK, Zhao X, Zhou C, Karp G, Welch EM, Naryshkin N, Ratni H, Chen KS, Metzger F, Paushkin S, Weetall M, Ko CP.
    Hum Mol Genet; 2016 Mar 01; 25(5):964-75. PubMed ID: 26758873
    [Abstract] [Full Text] [Related]

  • 7. Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy.
    Zhou H, Meng J, Malerba A, Catapano F, Sintusek P, Jarmin S, Feng L, Lu-Nguyen N, Sun L, Mariot V, Dumonceaux J, Morgan JE, Gissen P, Dickson G, Muntoni F.
    J Cachexia Sarcopenia Muscle; 2020 Jun 01; 11(3):768-782. PubMed ID: 32031328
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis.
    Morrison BM, Lachey JL, Warsing LC, Ting BL, Pullen AE, Underwood KW, Kumar R, Sako D, Grinberg A, Wong V, Colantuoni E, Seehra JS, Wagner KR.
    Exp Neurol; 2009 Jun 01; 217(2):258-68. PubMed ID: 19285073
    [Abstract] [Full Text] [Related]

  • 11. Advances and limitations for the treatment of spinal muscular atrophy.
    Day JW, Howell K, Place A, Long K, Rossello J, Kertesz N, Nomikos G.
    BMC Pediatr; 2022 Nov 03; 22(1):632. PubMed ID: 36329412
    [Abstract] [Full Text] [Related]

  • 12. Co-Administration of Myostatin-Targeting siRNA and ActRIIB-Fc Fusion Protein Increases Masseter Muscle Mass and Fiber Size.
    Bayarsaikhan O, Kawai N, Mori H, Kinouchi N, Nikawa T, Tanaka E.
    J Nutr Sci Vitaminol (Tokyo); 2017 Nov 03; 63(4):244-248. PubMed ID: 28978871
    [Abstract] [Full Text] [Related]

  • 13. Myostatin inhibition by a follistatin-derived peptide ameliorates the pathophysiology of muscular dystrophy model mice.
    Tsuchida K.
    Acta Myol; 2008 Jul 03; 27(1):14-8. PubMed ID: 19108572
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Impact of Disease Severity and Disease-Modifying Therapies on Myostatin Levels in SMA Patients.
    Mackels L, Mariot V, Buscemi L, Servais L, Dumonceaux J.
    Int J Mol Sci; 2024 Aug 12; 25(16):. PubMed ID: 39201450
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Chronic treatment with lithium does not improve neuromuscular phenotype in a mouse model of severe spinal muscular atrophy.
    Dachs E, Piedrafita L, Hereu M, Esquerda JE, Calderó J.
    Neuroscience; 2013 Oct 10; 250():417-33. PubMed ID: 23876328
    [Abstract] [Full Text] [Related]

  • 18. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.
    Benny Klimek ME, Aydogdu T, Link MJ, Pons M, Koniaris LG, Zimmers TA.
    Biochem Biophys Res Commun; 2010 Jan 15; 391(3):1548-54. PubMed ID: 20036643
    [Abstract] [Full Text] [Related]

  • 19. The role of myostatin and activin receptor IIB in the regulation of unloading-induced myofiber type-specific skeletal muscle atrophy.
    Babcock LW, Knoblauch M, Clarke MS.
    J Appl Physiol (1985); 2015 Sep 15; 119(6):633-42. PubMed ID: 26205544
    [Abstract] [Full Text] [Related]

  • 20. Role of satellite cells versus myofibers in muscle hypertrophy induced by inhibition of the myostatin/activin signaling pathway.
    Lee SJ, Huynh TV, Lee YS, Sebald SM, Wilcox-Adelman SA, Iwamori N, Lepper C, Matzuk MM, Fan CM.
    Proc Natl Acad Sci U S A; 2012 Aug 28; 109(35):E2353-60. PubMed ID: 22869749
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.